Hu et al. recently reported that pan-HDAC inhibitors that target the neural precursor cell-expressed developmentally down-regulated 9 (NEDD9)-focal adhesion kinase (FAK) pathway increase breast cancer metastasis in preclinical models, potentially seriously impeding the therapeutic success of these drugs. The gene discussed is HDAC9; the disease is breast carcinoma.